← Analysis page  ·  Pieter Slegers hub  ·  Research hub

Actionable insights — Buying 2 Stocks

A cash-flow goal reverse-engineered into a monthly contribution, valuation by yield rather than multiple, and position weight used as a buy trigger.
2026-FEB-22 · Compounding Quality (Substack) · Pieter Slegers · read ↗ · full analysis · transcript
How to read this page: each insight is a method used in this issue, written so it can be rerun on other names. Written post, so no timestamps.

1. Reverse-engineer a cash-flow goal into a monthly contribution

The repeatable method
  1. State the goal as an income figure rather than a portfolio value — it is easier to hold on to and harder to move.
  2. Divide by a realistic free-cash-flow yield to get the capital required. $525,600 a year at 5% is $10.5m.
  3. Solve for time using three published assumptions: current value, monthly contribution and expected return.
  4. Publish all three so the plan can be checked, and revisited when any of them changes.
  5. Notice which of the three is actually driving the outcome at your current stage — early on it is almost always the contribution, not the return.
Here: "$1 in Free Cash Flow per minute" = $525,600 a year; "At a FCF Yield of 5%, we would need a Portfolio of $10.5 million"; from "$1.4 million" plus "$50,000 every single month" at "12% per year" — "a little bit more than 7 years." The monthly add is ~3.5% of the current portfolio.
Watch for

2. Refuse market timing on the structure of the bet, not on a forecast

The repeatable method
  1. Point out that timing requires two correct decisions — when to sell and when to return — and that the second is the harder one.
  2. Add the asymmetry: the best days cluster immediately after the worst, so being out during the fall usually means being out during the recovery.
  3. Quantify the cost of missing a handful of days over a long window.
  4. Replace the judgement with a rule: stay invested, and add on a fixed schedule.
Here: "you need to be right twice… The best days on the stock market usually take place just after the worst ones. Just imagine you missed the 10 best trading days over the past 27 years… Your returns would only be a fraction of what they would be."
Watch for

3. Invert the valuation — quote a cash yield instead of a multiple

The repeatable method
  1. Convert the multiple into its reciprocal: free cash flow divided by market value, expressed as a percentage.
  2. Compare it against the company's own history rather than against a peer group — an all-time-high yield is an all-time-low valuation.
  3. Project it forward on estimates so the reader sees the yield the current price buys in two years.
  4. Use it because a yield is directly comparable to a bond, a savings rate or your own hurdle, in a way a multiple is not.
Here: CSU.TO — "a FCF Yield of 6.8% (the highest it has ever been)," and "for 2027… Expected FCF Yield: 9.7%." The same business was quoted at "16.2x cash flow" on 1 February and "just 16x FCF" on 12 February.
Watch for

4. Adjust reported free cash flow for deliberate growth spending

The repeatable method
  1. Ask whether the company is suppressing reported cash flow on purpose by reinvesting into growth — acquisitions, new capacity, R&D.
  2. If so, the reported yield understates what an owner could take out, and the stock is cheaper than the headline number.
  3. Test the claim by checking that the reinvestment earns a high return; otherwise "growth spending" is just spending.
  4. Say plainly that this is an adjustment, so the reader knows which number is reported and which is yours.
Here: "Constellation isn't even trying to maximize its Free Cash Flow yet. They are re-investing heavily in future growth. This means the stock is even cheaper in reality." The archive elsewhere formalises this as FCFA2S — free cash flow available to shareholders.
Watch for

5. Anchor a discount to a figure management publishes, then hold them to it

The repeatable method
  1. Use the company's own disclosed intrinsic value or plan target as the anchor, rather than your own DCF, when one exists.
  2. Express the gap as a discount to that number, and date it to the results release it came from.
  3. Record management's growth target alongside it — you are now underwriting a specific, checkable claim.
  4. Revisit both at the next results and note whether the figure moved for good reasons.
Here: BN — "Brookfield says its intrinsic value now equals $68. This means the company is trading at a 30% discount," plus the stated goal "to grow its intrinsic value by 15% per year." Distributable earnings: 20.4x (2025) → 18.1x (2026) → 15.8x (2027).
Watch for

6. Let an underweight position in a top-conviction name be an explicit buy trigger

The repeatable method
  1. Compare the conviction ranking against the weight ranking each month.
  2. Where a top-tier name sits at the bottom of the weight table, treat the gap as an unfinished decision rather than a coincidence.
  3. Close it deliberately and say so, pairing the sizing reason with a current valuation reason so the add is not mechanical.
Here: "Constellation Software has a low weight of 3.8% within Our Portfolio. It deserves a higher weight, especially at these valuation levels" — closing the gap the 15 February weight chart exposed, where a Strong Buy sat as one of the two smallest positions.
Watch for

7. Reconcile the order arithmetic before publishing it

The repeatable method
  1. Publish amount, quantity and limit price for every order so the reader can replicate it.
  2. Then multiply: quantity × limit should approximate the stated amount. If it does not, one of the three is wrong.
  3. Check the summary against the body — a restated figure in a conclusion is where transcription errors live.
Here: BN — the transaction block says "Q 730 with a limit price of CAD 47," the conclusion says CAD 64. Only CAD 47 × 730 reconciles with the stated $25,000. The 1 February issue has the same failure mode, reversing the Visa and Topicus amounts in its summary.
Watch for

Methods distilled from the archived Compounding Quality post for personal study. Not investment advice.